Concomitant retrograde coronary venous infusion of basic fibroblast growth factor enhances engraftment and differentiation of bone marrow mesenchymal stem cells for cardiac repair after myocardial infarction

Theranostics

Volumn 5, Issue 9, 2015, Pages 995-1006

  Wang, Xiao ^a   Zhen, Lei ^a   Miao, Huangtai ^a   Sun, Qiwei ^a   Yang, Ya ^a   Que, Bin ^a   Lao, Edmundo Patricio Lopes ^a   Wu, Xingxin ^a   Ren, Hongmei ^a   Shi, Shutian ^a   Lau, Wayne B ^b   Ma, Xinliang ^a,b   Ma, Changsheng ^a   Nie, Shaoping ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cell transplantation; Growth factor; Mesenchymal stem cells; Myocardial infarction; Retrograde

Indexed keywords

PHOSPHATE BUFFERED SALINE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; SOMATOMEDIN; VASCULOTROPIN; FIBROBLAST GROWTH FACTOR 2; PLACEBO;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL PARAMETERS; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANINE MODEL; CARDIOVASCULAR PARAMETERS; CELL DIFFERENTIATION; CELL MIGRATION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; ENGRAFTMENT; HEART INFARCT WALL THICKNESS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HISTOPATHOLOGY; HYPOXIA; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHENOTYPE; STEM CELL CULTURE; TRANSTHORACIC ECHOCARDIOGRAPHY; VASCULAR DENSITY; ANATOMY AND HISTOLOGY; ANIMAL; BIOMETRY; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CYTOCHEMISTRY; DISEASE MODEL; DOG; DRUG EFFECTS; ECHOCARDIOGRAPHY; HEART; INTRAVENOUS DRUG ADMINISTRATION; MESENCHYMAL STROMA CELL; MICROSCOPY; MYOCARDIAL INFARCTION; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BIOMETRY; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DOGS; ECHOCARDIOGRAPHY; FIBROBLAST GROWTH FACTOR 2; HEART; HISTOCYTOCHEMISTRY; INFUSIONS, INTRAVENOUS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICROSCOPY; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; PLACEBOS; TREATMENT OUTCOME;

EID: 84945967171     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11607     Document Type: Article

References (39)

1. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ. Cell therapy for cardiac repair--lessons from clinical trials. Nat Rev Cardiol. 2014; 11: 232-46. doi:10.1038/nrcardio.2014.9.
2. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011; 109: 923-40. doi:10.1161/CIRCRESAHA.111.243147.
3. Hatzistergos KE, Quevedo H, Oskouei BN, Hu Q, Feigenbaum GS, Margitich IS, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010; 107: 913-22. doi:10.1161/CIRCRESAHA.110.222703.
4. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, et al. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation. 2005; 111: 150-6. doi:10.1161/01.CIR. 0000151812.86142.45.
5. Tao B, Cui M, Wang C, Ma S, Wu F, Yi F, et al. Percutaneous intramyocardial delivery of mesenchymal stem cells induces superior improvement in regional left ventricular function compared with bone marrow mononuclear cells in porcine myocardial infarcted heart. Theranostics. 2015; 5: 196-205. doi:10.7150/thno.7976.
6. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014; 311: 62-73. doi:10.1001/jama.2013.282909.
7. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54: 2277-86. doi:10.1016/j.jacc.2009.06.055.
8. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A. 2009; 106: 14022-7. doi:10.1073/pnas.0903201106.
9. Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008; 103: 1204-19. doi:10.1161/CIRCRESAHA.108.176826.
10. Terrovitis JV, Smith RR, Marban E. Assessment and optimization of cell engraftment after transplantation into the heart. Circ Res. 2010; 106: 479-94. doi:10.1161/CIRCRESAHA.109.208991.
11. Yagi H, Soto-Gutierrez A, Parekkadan B, Kitagawa Y, Tompkins RG, Kobayashi N, et al. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant. 2010; 19: 667-79. doi:10.3727/096368910X508762.
12. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8: 235-53. doi:10.1038/nrd2792.
13. Schmidt A, Ladage D, Schinkothe T, Klausmann U, Ulrichs C, Klinz FJ, et al. Basic fibroblast growth factor controls migration in human mesenchymal stem cells. Stem Cells. 2006; 24: 1750-8. doi:10.1634/stemcells.2005-0191.
14. Song H, Kwon K, Lim S, Kang SM, Ko YG, Xu Z, et al. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells. 2005; 19: 402-7.
15. Dib N, Menasche P, Bartunek JJ, Zeiher AM, Terzic A, Chronos NA, et al. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv. 2010; 3: 265-75. doi:10.1016/j.jcin.2009.12.013.
16. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J. 2006; 27: 1114-22. doi:10.1093/eurheartj/ehi818.
17. Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ. Incomplete retention after direct myocardial injection. Catheter Cardiovasc Interv. 2002; 55: 392-7. doi:10.1002/ccd.10136.
18. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013; 113: 810-34. doi:10.1161/CIRCRESAHA.113.300219.
19. Hou D, Youssef EA, Brinton TJ, Zhang P, Rogers P, Price ET, et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation. 2005; 112: I150-6. doi:10.1161/CIRCULATIONAHA.104.526749.
20. Fearon WF, Ikeno F, Bailey LR, Hiatt BL, Herity NA, Carter AJ, et al. Evaluation of high-pressure retrograde coronary venous delivery of FGF-2 protein. Catheter Cardiovasc Interv. 2004; 61: 422-8. doi:10.1002/ccd.10790.
21. Wang X, Nie S-P, Zhen L, Miao H-T, Wu X-X, Ren H-M, et al. Retrograde coronary venous infusion provides targeted cell engraftment into infarcted myocardium. Int J Cardiol. 2014; 172: e279-e81. doi:10.1016/j.ijcard.2013.12.202.
22. Suzuki K, Murtuza B, Fukushima S, Smolenski RT, Varela-Carver A, Coppen SR, et al. Targeted cell delivery into infarcted rat hearts by retrograde intracoronary infusion: distribution, dynamics, and influence on cardiac function. Circulation. 2004; 110: II225-30. doi:10.1161/01.CIR. 0000138191.11580.e3.
23. Pfister O, Della Verde G, Liao R, Kuster GM. Regenerative therapy for cardiovascular disease. Transl Res. 2014; 163: 307-20. doi:10.1016/j.trsl.2013.12.005.
24. Garbern JC, Lee RT. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell. 2013; 12: 689-98. doi:10.1016/j.stem.2013.05.008.
25. Bolli R, Tang XL, Sanganalmath SK, Rimoldi O, Mosna F, Abdel-Latif A, et al. Intracoronary delivery of autologous cardiac stem cells improves cardiac function in a porcine model of chronic ischemic cardiomyopathy. Circulation. 2013; 128: 122-31. doi:10.1161/CIRCULATIONAHA.112.001075.
26. Bolli R, Chugh AR, D'Amario D, Loughran JH, Stoddard MF, Ikram S, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011; 378: 1847-57. doi:10.1016/S0140-6736(11)61590-0.
27. Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012; 379: 895-904. doi:10.1016/S0140-6736(12)60195-0.
28. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol. 2005; 46: 1339-50. doi:10.1016/j.jacc.2005.05.079.
29. Takehara N, Tsutsumi Y, Tateishi K, Ogata T, Tanaka H, Ueyama T, et al. Controlled delivery of basic fibroblast growth factor promotes human cardiosphere-derived cell engraftment to enhance cardiac repair for chronic myocardial infarction. J Am Coll Cardiol. 2008; 52: 1858-65. doi:10.1016/j.jacc.2008.06.052.
30. Ye L, Zhang P, Duval S, Su L, Xiong Q, Zhang J. Thymosin beta4 increases the potency of transplanted mesenchymal stem cells for myocardial repair. Circulation. 2013; 128: S32-41. doi:10.1161/CIRCULATIONAHA.112.000025.
31. Houtgraaf JH, de Jong R, Kazemi K, de Groot D, van der Spoel TI, Arslan F, et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ Res. 2013; 113: 153-66. doi:10.1161/CIRCRESAHA.112.300730.
32. Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med. 2000; 6: 1282-6. doi:10.1038/81395.
33. Rodrigues M, Griffith LG, Wells A. Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res Ther. 2010; 1: 32. doi:10.1186/scrt32.
34. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell. 2012; 10: 244-58. doi:10.1016/j.stem.2012.02.005.
35. Vrtovec B, Poglajen G, Lezaic L, Sever M, Socan A, Domanovic D, et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation. 2013; 128: S42-9. doi:10.1161/CIRCULATIONAHA.112.000230.
36. Jain AK, Smith EJ, Rothman MT. The coronary venous system: an alternative route of access to the myocardium. J Invasive Cardiol. 2006; 18: 563-8.
37. Yokoyama S, Fukuda N, Li Y, Hagikura K, Takayama T, Kunimoto S, et al. A strategy of retrograde injection of bone marrow mononuclear cells into the myocardium for the treatment of ischemic heart disease. J Mol Cell Cardiol. 2006; 40: 24-34. doi:10.1016/j.yjmcc.2005.06.008.
38. Sato T, Iso Y, Uyama T, Kawachi K, Wakabayashi K, Omori Y, et al. Coronary vein infusion of multipotent stromal cells from bone marrow preserves cardiac function in swine ischemic cardiomyopathy via enhanced neovascularization. Lab Invest. 2011; 91: 553-64. doi:10.1038/labinvest.2010.202.
39. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010; 56: 721-34. doi:10.1016/j.jacc.2010.03.066.